Navigation Links
PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust
Date:12/22/2011

SOUTH PLAINFIELD, N.J., Dec. 22, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from the Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria.  PTC previously received a $5.4 million SDD Award from the Wellcome Trust to support its BMI1 oncology program.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The discovery and development of new and novel antibiotics are urgently needed due to the increased frequency of bacterial resistance to marketed antibiotics in the hospital and community settings.  Hospital-acquired infections present a major threat to patient health and quality of life.  The Centers for Disease Control and Prevention estimates that approximately 1.7 million hospital-acquired bacterial infections cause or contribute to nearly 100,000 deaths in the United States each year with similar data reported from Europe.  Gram-negative bacteria are responsible for more than 30 percent of these infections.  The major concern with MDR Gram-negative bacteria is there are limited options to effectively treat them.

"We are honored to expand our relationship with the Wellcome Trust through this second award," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer at PTC Therapeutics.  "This funding will support our ongoing efforts to develop novel antibiotics to treat infections caused by multidrug-resistant Gram-negative bacteria."

PTC has identified a novel structural class of molecules that have potent activity against Gram-negative bacteria that are resistant to marketed antibiotics.  The anti-infective program at PTC is currently in lead optimization and advancing towards identifying a Development Candidate.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
2. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
3. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
4. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
5. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
6. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
7. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
8. Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
9. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
10. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
11. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... issued the following statement today in support of President ... "As the global leader in rapid diagnostics ... a national strategy to address the serious threat of ... with the Administration on initiatives to promote the development ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Nerve Growth Factor Has Demonstrated Promising Activity Preclinically-- , ... Huntington,s Disease and Others-- , , RESEARCH TRIANGLE ... clinical stage company developing and commercializing innovative treatments for ... that it has obtained the rights to develop and ...
... June 15 Vitamin D deficiency was found to be ... the results of a recent study conducted at ... these results, CTCA researchers determined that screening for vitamin D ... all people with cancer. , , (Logo: ...
Cached Medicine Technology:CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 2CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders 3Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients 2
(Date:9/20/2014)... September 20, 2014 The print ... today’s edition of the Calgary Herald, with a ... readership of 270,000. The digital component is distributed ... across a network of top news sites and ... the campaign, visit http://www.worklifebalanceinfo.ca . , The ...
(Date:9/20/2014)... -- The avian flu that killed 160 harbor seals ... respiratory drops and therefore poses a potential threat to ... human illnesses have been linked to the harbor seal ... discovered natural mutations to the avian H3N8 seal virus ... in droplets. Current seasonal flu vaccines wouldn,t help ...
(Date:9/20/2014)... festival season is coming soon. The high-end fashion designer BellasDress ... dresses . A lot of sophisticated women like its new ... promotion for its high quality clothes. Now, each of its ... to 71 percent off. , The company’s cocktail dress ... in many fashionable colors. Mary, the company’s sales manager, believes ...
(Date:9/20/2014)... TX (PRWEB) September 20, 2014 ... Forecast and Market Analysis to 2023?. The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ...
(Date:9/20/2014)... the popular online supplier of wedding dresses and special ... collection of cocktail gowns. This afternoon, the company announced ... outfits; it intends to expand its online market in ... cocktail dresses in the company’s online store. ... experience in the industry of women’s special occasion dresses. ...
Breaking Medicine News(10 mins):Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Fashionable Cocktail Dresses Unveiled Online at iFitDress.com 2
... Dynatronics,Corporation (Nasdaq: DYNT ) today announced ... Mike Draper and Tom Draper, both of Wichita, ... as direct sales representatives. Dynatronics now offers ... our direct distribution presence is helping improve,profit margins ...
... BIRMINGHAM, Ala., Oct. 10 Aeon Bioscience,Inc. ... of its key,collaborators, Brookwood Pharmaceuticals, Inc. by ... to develop improvements in drug-eluting stent,technology for ... Bioscience was formed as a collaborative enterprise ...
... Achievement,and Innovation in Patient-Centered Approaches to Care, ... Hospital of,Warrenton, VA has been formally recognized ... Hospital." This designation,recognizes Fauquier,s achievement and innovation ... prioritizes patient comfort, dignity, empowerment,and well-being, while ...
... eHI Blueprint Offers Multi-Stakeholder Consensus on a Shared Vision, ... ... Through Information Technology, WASHINGTON, Oct. 10 Today the ... Common Action, which represents multi-stakeholder,consensus on a shared vision and ...
... A report to be published in an upcoming issue ... urgent attention to the politically sensitive issue of border control, ... the face of a catastrophic flu pandemic . The ... a strain of avian influenza A (HN51) in Northern Sumatra: ...
... Oct. 10 CBIZ, Inc. (NYSE: CBZ ) has,scheduled ... a.m.,(ET) to discuss the Company,s financial results for the third-quarter ... the,market opens the morning of October 25, 2007. At that ... Company,s web site at http://www.cbiz.com . The call ...
Cached Medicine News:Health News:Dynatronics Adds Three Additional Direct Sales Reps 2Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 2Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 3Health News:Aeon Bioscience Continues Development of Drug Eluting Stents 4Health News:Fauquier Hospital - One of Only Five Nationwide to Receive Formal Designation as Patient-Centered Hospital 2Health News:Fauquier Hospital - One of Only Five Nationwide to Receive Formal Designation as Patient-Centered Hospital 3Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 2Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 3Health News:eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT 4Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:CBIZ Webcasts Third-Quarter 2007 Conference Call 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Requires minimal cervical spine manipulation. Prevent dental ... nasally. Cost effective alternative to X-ray. Light-guided ... the soft tissues in the neck. This ... of the trachea relative to the esophagus. ...
Medicine Products: